nucleus research bpc 157 BPC-157 | 99%+ Purity BPC-157 Research Overview (2026) |
Description
Published preclinical studies have evaluated AOD 9604 at microgram-level doses in animal models, with administration routes varying by experimental design
- People with active or recent cancer history (the trial record contains a small number of cancers in the 12-week oral arm
Patients seeking moderate weight loss (10-15% body weight): Orforglipron's Phase 3 data show mean weight loss of approximately 11% at 72 weeks, with about 55% of participants achieving 10% or greater loss
I try to remove clumps once or twice a day and monitor the clumps etc
